Mitchell Capital Management Co. Trims Stake in Eli Lilly and Company $LLY

Mitchell Capital Management Co. lowered its position in Eli Lilly and Company (NYSE:LLY) by 43.3% during the 2nd quarter, HoldingsChannel reports. The fund owned 7,035 shares of the company’s stock after selling 5,376 shares during the period. Mitchell Capital Management Co.’s holdings in Eli Lilly and Company were worth $5,429,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in LLY. Index Fund Advisors Inc. grew its holdings in shares of Eli Lilly and Company by 159.7% in the second quarter. Index Fund Advisors Inc. now owns 1,218 shares of the company’s stock worth $950,000 after purchasing an additional 749 shares during the last quarter. M3 Advisory Group LLC grew its holdings in shares of Eli Lilly and Company by 5.0% in the second quarter. M3 Advisory Group LLC now owns 636 shares of the company’s stock worth $496,000 after purchasing an additional 30 shares during the last quarter. Yarger Wealth Strategies LLC grew its holdings in shares of Eli Lilly and Company by 24.1% in the second quarter. Yarger Wealth Strategies LLC now owns 577 shares of the company’s stock worth $450,000 after purchasing an additional 112 shares during the last quarter. Sharp Financial Services LLC grew its holdings in shares of Eli Lilly and Company by 13.1% in the second quarter. Sharp Financial Services LLC now owns 431 shares of the company’s stock worth $336,000 after purchasing an additional 50 shares during the last quarter. Finally, Mitchell Sinkler & Starr PA grew its holdings in shares of Eli Lilly and Company by 1.2% in the second quarter. Mitchell Sinkler & Starr PA now owns 2,431 shares of the company’s stock worth $1,895,000 after purchasing an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other news, CEO David A. Ricks purchased 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 4,514 shares of company stock worth $2,894,841. Insiders own 0.14% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. JPMorgan Chase & Co. cut their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, September 16th. Leerink Partners restated a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $948.06.

Eli Lilly and Company Trading Down 2.6%

NYSE LLY opened at $833.08 on Monday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $788.47 billion, a price-to-earnings ratio of 54.45, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. The company’s 50-day simple moving average is $742.42 and its two-hundred day simple moving average is $765.55. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.